Barriers to Accessing New Anti-Diabetes Medications
Medical experts underscore disparities in diabetes treatment access, stressing the impact of insurance plans on treatment decisions, which can hinder patients and providers, especially when considering newer medications like GLP-1 agonists.
EP: 1.Defining Resistant Diabetes
EP: 2.Differentiating Medication Non-Adherence From Underlying Comorbidities
Now Viewing
EP: 3.Barriers to Accessing New Anti-Diabetes Medications
EP: 4.Suspecting Hypercortisolism in Patients With Resistant Diabetes
EP: 5.Testing for Hypercortisolism
EP: 6.Patient Subgroups With a Higher Prevalence of Hypercortisolism
EP: 7.Evolving Perception of Autonomous Adrenal Hypercortisolism
EP: 8.Pathophysiology of Hypercortisolism
EP: 9.Need to Address Underlying Hypercortisolism
EP: 10.Approaching Treatment in Hypercortisolism
EP: 11.Choosing Between Medical and Surgical Options for Hypercortisolism
EP: 12.Long-Term Outcomes for Patients Treated for Hypercortisolism
Recent Videos
Related Content
